IL165478A - Humanized anti-myelin associated glycoprotein (mag) antibody and pharmaceutical composition comprising such antibody - Google Patents

Humanized anti-myelin associated glycoprotein (mag) antibody and pharmaceutical composition comprising such antibody

Info

Publication number
IL165478A
IL165478A IL165478A IL16547804A IL165478A IL 165478 A IL165478 A IL 165478A IL 165478 A IL165478 A IL 165478A IL 16547804 A IL16547804 A IL 16547804A IL 165478 A IL165478 A IL 165478A
Authority
IL
Israel
Prior art keywords
antibody
mag
pharmaceutical composition
humanized anti
associated glycoprotein
Prior art date
Application number
IL165478A
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0218234A external-priority patent/GB0218234D0/en
Priority claimed from GB0218232A external-priority patent/GB0218232D0/en
Priority claimed from GB0218230A external-priority patent/GB0218230D0/en
Priority claimed from GB0218229A external-priority patent/GB0218229D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL165478A publication Critical patent/IL165478A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL165478A 2002-08-06 2004-11-30 Humanized anti-myelin associated glycoprotein (mag) antibody and pharmaceutical composition comprising such antibody IL165478A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0218234A GB0218234D0 (en) 2002-08-06 2002-08-06 Antibodies
GB0218232A GB0218232D0 (en) 2002-08-06 2002-08-06 Antibodies
GB0218230A GB0218230D0 (en) 2002-08-06 2002-08-06 Antibodies
GB0218229A GB0218229D0 (en) 2002-08-06 2002-08-06 Antibodies
PCT/EP2003/008749 WO2004014953A2 (en) 2002-08-06 2003-08-05 Anti-myelin associated glycoprotein (mag) antibodies

Publications (1)

Publication Number Publication Date
IL165478A true IL165478A (en) 2010-12-30

Family

ID=31721633

Family Applications (1)

Application Number Title Priority Date Filing Date
IL165478A IL165478A (en) 2002-08-06 2004-11-30 Humanized anti-myelin associated glycoprotein (mag) antibody and pharmaceutical composition comprising such antibody

Country Status (24)

Country Link
US (2) US7612183B2 (en)
EP (1) EP1526868B1 (en)
JP (1) JP4528121B2 (en)
KR (1) KR101078459B1 (en)
CN (1) CN100542607C (en)
AR (1) AR040778A1 (en)
AU (1) AU2003255390B2 (en)
BR (1) BR0312456A (en)
CA (1) CA2494008C (en)
CY (1) CY1114919T1 (en)
DK (1) DK1526868T3 (en)
ES (1) ES2440652T3 (en)
HK (1) HK1077206A1 (en)
IL (1) IL165478A (en)
IS (1) IS7576A (en)
MX (1) MXPA05001468A (en)
MY (1) MY148409A (en)
NO (1) NO333876B1 (en)
NZ (1) NZ537123A (en)
PL (1) PL211014B1 (en)
PT (1) PT1526868E (en)
SI (1) SI1526868T1 (en)
TW (1) TWI323265B (en)
WO (1) WO2004014953A2 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002231736A1 (en) 2000-12-22 2002-07-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of repulsive guidance molecule (rgm) and its modulators
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
AR040778A1 (en) * 2002-08-06 2005-04-20 Glaxo Group Ltd ALTERED ANTIBODIES OR FUNCTIONAL FRAGMENTS THAT BIND MAG (GLICOPROTEIN ASSOCIATED WITH HONEY).
GB0306309D0 (en) * 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
CN101213297B (en) * 2005-05-09 2013-02-13 小野药品工业株式会社 Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
EP1928905B1 (en) 2005-09-30 2015-04-15 AbbVie Deutschland GmbH & Co KG Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
CN107929731A (en) 2005-11-04 2018-04-20 健泰科生物技术公司 Utilize complement pathway inhibitors to treat ocular diseases
JP2009536641A (en) * 2006-05-31 2009-10-15 ハンワ ケミカル コーポレイション VCAM-1-specific monoclonal antibody
ES2700609T3 (en) 2006-11-02 2019-02-18 Genentech Inc Humanized anti-factor D antibodies and their uses
US20100291108A1 (en) * 2007-10-16 2010-11-18 Arie Abo Antibodies to irem-1
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
CR20170001A (en) 2008-04-28 2017-08-10 Genentech Inc ANTI FACTOR D HUMANIZED ANTIBODIES
US20110064821A1 (en) 2008-05-06 2011-03-17 Catchpole Ian Richard Encapsulation of biologically active agents
UY32341A (en) 2008-12-19 2010-07-30 Glaxo Group Ltd NEW ANTIGEN UNION PROTEINS
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
TW201031421A (en) * 2009-01-29 2010-09-01 Abbott Lab IL-1 binding proteins
MX2012006560A (en) 2009-12-08 2012-10-05 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration.
WO2011085289A1 (en) * 2010-01-11 2011-07-14 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Production of a monoclonal antibody therapeutic against west nile virus in plants
AR081556A1 (en) 2010-06-03 2012-10-03 Glaxo Group Ltd HUMANIZED ANTIGEN UNION PROTEINS
AU2011267869A1 (en) 2010-06-14 2013-01-10 Vaccinex, Inc. Anti-VEGF antibodies and uses thereof
US8974782B2 (en) * 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies
IL297229A (en) 2012-01-27 2022-12-01 Abbvie Inc Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
KR20180021234A (en) 2013-08-12 2018-02-28 제넨테크, 인크. Compositions and method for treating complement-associated conditions
CN105829542A (en) 2013-12-20 2016-08-03 豪夫迈·罗氏有限公司 Improved recombinant polypeptide production methods
JP6502374B2 (en) 2014-03-13 2019-04-17 ウニヴェルズィテート バーゼル Carbohydrate ligand binding to IgM antibodies against myelin related glycoproteins
WO2015168468A1 (en) 2014-05-01 2015-11-05 Genentech, Inc. Anti-factor d antibody variants and uses thereof
CR20170562A (en) 2015-06-24 2018-02-01 Hoffmann La Roche TRANSFERRINE ANTI-RECEIVER ANTIBODIES WITH DESIGNATED AFFINITY.
WO2017046172A1 (en) 2015-09-16 2017-03-23 Universität Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
AR106184A1 (en) * 2015-09-29 2017-12-20 Celgene Corp PD-1 BINDING PROTEINS AND THEIR METHODS OF USE
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
EP3356406A1 (en) 2015-10-02 2018-08-08 H. Hoffnabb-La Roche Ag Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
JP2018534930A (en) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド Anti-factor D antibodies and conjugates
KR102257154B1 (en) 2016-09-19 2021-05-28 셀진 코포레이션 Methods of treating immune diseases using PD-1 binding protein
WO2018053401A1 (en) 2016-09-19 2018-03-22 Celgene Corporation Methods of treating vitiligo using pd-1 binding proteins
CN109481673A (en) * 2017-09-12 2019-03-19 中国科学院苏州纳米技术与纳米仿生研究所 The composition of promotion cerebral injury neural restoration and its application and evaluation method

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DK84787D0 (en) 1987-02-19 1987-02-19 Axel Olsen LISTING SYSTEM FOR ELECTRIC POWER SUPPLY AND / OR POWER CONTROLLERS
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
US5154927A (en) * 1989-01-19 1992-10-13 Wm. Wrigley Jr. Company Gum composition containing dispersed porous beads containing active chewing gum ingredients and method
US5154924A (en) 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5182107A (en) 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5527527A (en) 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
FI93513C (en) 1993-11-04 1995-04-25 Matti Kangasvuori Chain and method of making a chain
EP0804237B8 (en) * 1994-01-25 2006-11-08 Elan Pharmaceuticals, Inc. Humanized antibodies against leukocyte adhesion molecule vla-4
GB9403250D0 (en) * 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US6576607B1 (en) * 1995-04-19 2003-06-10 Acorda Therapeutics Methods using CNS neurite outgrowth modulators
TR199801650T2 (en) 1995-04-19 1999-03-22 Acorda Therapeutics MMS n�rit b�y�me mod�lat�rleri ve bile�imleri.
US5792743A (en) * 1995-04-19 1998-08-11 Acorda Therapeutics Method for promoting neural growth comprising administering a soluble neural cell adhesion molecule
CA2225691A1 (en) * 1995-06-27 1997-01-16 Research Foundation Of Cuny, Hunter College Compositions and methods using myelin-associated glycoprotein (mag) and inhibitors thereof
EP0842948B1 (en) * 1995-06-30 2009-04-22 Mochida Pharmaceutical Co., Ltd. ANTIFas LIGAND ANTIBODIES AND ASSAY METHOD BY USING THE SAME
WO1997007810A1 (en) 1995-08-25 1997-03-06 The John Hopkins University School Of Medicine Compounds for stimulating nerve growth
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
JP2001515345A (en) * 1996-09-20 2001-09-18 ザ・ジェネラル・ホスピタル・コーポレイション Compositions and methods for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin
WO1999021581A1 (en) * 1997-10-28 1999-05-06 Steeves John D Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration
KR20010015817A (en) 1997-11-14 2001-02-26 유로-셀티큐 에스.에이. Modified Antibodies with Enhanced Ability to elicit an anti-idiotype response
WO1999053945A1 (en) * 1998-04-16 1999-10-28 Samuel David Neuron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
ATE483021T1 (en) 1998-07-22 2010-10-15 Smithkline Beecham Ltd PROTEIN SIMILAR TO A NEUROENDOCRINE-SPECIFIC PROTEIN AND CDNS CODING THEREFOR
CZ304224B6 (en) 1998-11-06 2014-01-15 Schwab Monoclonal antibody
JP2002535289A (en) 1999-01-22 2002-10-22 ドウアリング，マシユー・ジヨン Vaccine-mediated treatment of neurological disorders
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
JP4656478B2 (en) * 2000-02-22 2011-03-23 株式会社医学生物学研究所 Antibody library
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
US20040002790A1 (en) * 2002-06-28 2004-01-01 Paul Senn Sensitive devices and sensitive applications
AR040778A1 (en) 2002-08-06 2005-04-20 Glaxo Group Ltd ALTERED ANTIBODIES OR FUNCTIONAL FRAGMENTS THAT BIND MAG (GLICOPROTEIN ASSOCIATED WITH HONEY).
GB0306309D0 (en) * 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment

Also Published As

Publication number Publication date
MY148409A (en) 2013-04-30
AU2003255390A1 (en) 2004-02-25
PL375405A1 (en) 2005-11-28
US8071731B2 (en) 2011-12-06
TWI323265B (en) 2010-04-11
KR101078459B1 (en) 2011-10-31
CN100542607C (en) 2009-09-23
IS7576A (en) 2004-11-30
JP4528121B2 (en) 2010-08-18
JP2006512899A (en) 2006-04-20
DK1526868T3 (en) 2014-01-13
US7612183B2 (en) 2009-11-03
EP1526868B1 (en) 2013-10-23
PT1526868E (en) 2014-01-07
CN1671417A (en) 2005-09-21
ES2440652T3 (en) 2014-01-29
CY1114919T1 (en) 2016-12-14
AU2003255390B2 (en) 2011-02-03
WO2004014953A3 (en) 2004-05-06
TW200403254A (en) 2004-03-01
AR040778A1 (en) 2005-04-20
WO2004014953A2 (en) 2004-02-19
CA2494008A1 (en) 2004-02-19
BR0312456A (en) 2005-04-19
KR20050049470A (en) 2005-05-25
CA2494008C (en) 2012-12-11
HK1077206A1 (en) 2006-02-10
NO333876B1 (en) 2013-10-07
NZ537123A (en) 2007-05-31
SI1526868T1 (en) 2014-01-31
US20060165681A1 (en) 2006-07-27
MXPA05001468A (en) 2005-06-06
NO20045323L (en) 2005-02-10
US20090053214A1 (en) 2009-02-26
EP1526868A2 (en) 2005-05-04
PL211014B1 (en) 2012-03-30

Similar Documents

Publication Publication Date Title
IL165478A (en) Humanized anti-myelin associated glycoprotein (mag) antibody and pharmaceutical composition comprising such antibody
IL164021A (en) Anti-alphavbeta6 antibodies and pharmaceutical compositions containing the same
IL211385A0 (en) Anti-cd33 antibodies or epitope-binding fragments thereof and pharmaceutical compositions containing the same
EP1551447A4 (en) Anti-addl antibodies and uses thereof
EP1572131A4 (en) Antibody therapy
IL158643A (en) Anti-hmg monoclonal antibodies and compositions containing the same
EP1450824A4 (en) Pharmaceutical composition
EP1499352A4 (en) Recombinant anti-interleukin-9 antibodies
EP1539129A4 (en) Dosage forms and related therapies
HUP0303163A3 (en) Tramadol-based pharmaceutical composition
GB0117057D0 (en) Pharmaceutical composition
AU2003299581A8 (en) Antibodies against drugs of abuse
AU2002365649A8 (en) Anti-dota antibody
EG24516A (en) Peptide deformylase inhibitors
EP1408896A4 (en) Pharmaceutical composition
GB0129117D0 (en) Pharmaceutical composition
GB0116107D0 (en) Pharmaceutical composition
IL166063A0 (en) Antibodies and uses thereof
AU2003210054A1 (en) Anti-rank monoclonal antibodies and pharmaceutical composition containing the same
GB0127805D0 (en) Pharmaceutical composition
EP1456647A4 (en) Methods for identifying and validating potential drug targets---
AU2002255634A1 (en) Peptide deformylase inhibitors
AU2003212418A8 (en) Peptide deformylase
EP1437363A4 (en) Drug transporter and use thereof
AU2003270518A8 (en) Therapeutic anti-bgp(c-cam1) antibodies and uses thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees